References
- Cancer in Slovenia 2013. Ljubljana: Institute of Oncology Ljubljana, Epidemiology and Cancer Registry, Cancer Registry of Republic of Slovenia; 2016.
- Zadnik V, Primic Zakelj M, Lokar K, Jarm K, Ivanus U, Zagar T. Cancer burden in slovenia with the time trends analysis. Radiol Oncol 2017; 51: 47-55. 10.1515/raon-2017-0008
- Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JWW, Comber H, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer 2013; 49: 1374-403. 10.1016/j.ejca.2012.12.027
- Dummer R, Hauschild A, Lindenblatt N, Pentheroudakis G, Keilholz U. Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010; 21(Suppl 5): v194-7. 10.1093/annonc/mdv297
- Shtivelman E, Davies MQ, Hwu P, Yang J, Lotem M, Oren M, et al. Pathways and therapeutic targets in melanoma. Oncotarget 2014; 5: 1701-52. 10.18632/oncotarget.1892
- COSMIC, Catalogue of Somatic Mutations in Cancer. [citated 2017 Oct 10]. Available at http://cancer.sanger.ac.uk/cosmic
- Mandalà M, Voit C.Targeting BRAF in melanoma: biological and clinical challenges. Crit Rev Oncol Hematol 2013; 87: 239-55. 10.1016/j.critrevonc.2013.01.003
- McArthur GA, Chapman PB, Robert C, Larkin J, Haanen JB, Dummer R, et al. Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. Lancet Oncol 2014;15: 323-32. 10.1016/S1470-2045(14)70012-9
- Colombino M, Capone M, Lissia A, Cossu A, Rubino C, De Giorgi V, et al. BRAF/NRAS mutation frequencies among primary tumors and metastases in patients with melanoma. J Clin Oncol 2012; 30: 2522-9. 10.1200/JCO.2011.41.2452
- Jakob JA, Bassett RL Jr, Ng CS, Curry JL, Joseph RW, Alvarado GC, et al. NRAS mutation status is an independent prognostic factor in metastatic melanoma. Cancer 2012; 118: 4014-23. 10.1002/cncr.26724
- Curtin JA, Busam K, Pinkel D, Bastian BC. Curtin JA, et al. Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol 2006; 24: 4340-6. 10.1200/JCO.2006.06.2984
- Pracht M, Mogha A, Lespagnol A, Fautrel A, Mouchet N, Le Gall F, et al. Prognostic and predictive values of oncogenic BRAF, NRAS, c-KIT and MITF in cutaneous and mucous melanoma. J Eur Acad Dermatol Venereol 2015; 29:1530-8. 10.1111/jdv.12910
- Curtin JA, Fridlyand J, Kageshita T, Patel HN, Busam KJ, Kutzner H, et al. Distinct sets of genetic alterations in melanoma. N Engl J Med 2005; 353: 2135-47. 10.1056/NEJMoa050092
- Kim SY, Kim HJ, Hahn HJ, Lee YW, Choe YB, Ahn KJ. Meanalysis of BRAF mutations and clinical-pathologiy characteistics in primary melanoma. J Am Acad Dermatol 2015; 72: 1036-46.e2. 10.1016/j.jaad.2015.02.1113
- Yamazaki N, Tanaka R, Tsutsumida A, Namikawa K, Eguchi H, Omata W, et al. BRAF V600 mutations and pathological features in Japanese melanoma patients. Melanoma Res 2015; 25: 9-14. 10.1097/CMR.0000000000000091
- Menzies AM, Haydu LE, Visintin L, Carlino MS, Howle JR, Thompson JF, et al. Distinguishing clinical-pathologic features of patients with V600E and V600K BRAF-mutant metastatic melanoma. Clin Cancer Res 2012; 18: 3242-9. 10.1158/1078-0432.CCR-12-0052
- Bauer J, Büttner P, Murali R, Okamoto I, Kolaitis NA, Landi MT, et al. BRAF mutations in cutaneous melanoma are independently associated with age, anatomic site of the primary tumor, and the degree of solar elastosis at the primary tumor site. Pigment Cell Melanoma Res 2011; 24: 345-51. 10.1111/j.1755-148X.2011.00837.x
- Carlino MS, Haydu LE, Kakavand H, Menzies AM, Hamilton AL, Yu B, et al. Correlation of BRAF and NRAS mutation status with outcome, site of distant metastasis and response to chemotherapy in metastatic melanoma. Br J Cancer 2014; 111: 292-9. 10.1038/bjc.2014.287
- Devitt B, Liu W, Salemi R, Wolfe R, Kelly J, Tzen CY, et al. Clinical outcome and pathological features associated with NRAS mutation in cutaneous melanoma. Pigment Cell Melanoma Res 2011; 24: 666-72. 10.1111/j.1755-148X.2011.00873.x
- Lee JH, Choi JW, Kim YS. Frequencies of BRAF and NRAS mutations are different in histological types and sites of origin of cutaneous melanoma: a meta-analysis. Br J Dermatol 2011; 164: 776-84. 10.1111/j.1365-2133.2010.10185.x
- Hodis E, Watson IR, Kryukov GV, Arold ST, Imielinski M, Theurillat JP, et al. A landscape of driver mutations in melanoma. Cell 2012; 150: 251-63. 10.1016/j.cell.2012.06.024
- Valachis A, Ullenhag GJ. Discrepancy in BRAF status among patients with metastatic malignant melanoma: A meta-analysis. Eur J Cancer 2017; 81: 106-15. 10.1016/j.ejca.2017.05.015
- Long GV, Menzies AM, Nagrial AM, Haydu LE, Hamilton AL, Mann GJ, et al. Prognostic and clinical-pathologic associations of oncogenic BRAF in metastatic melanoma. J Clin Oncol 2011; 29: 1239-46. 10.1200/JCO.2010.32.4327
- Edlundh-Rose E, Egyházi S, Omholt K, Månsson-Brahme E, Platz A, Hansson J, et al. NRAS and BRAF mutations in melanoma tumours in relation to clinical characteristics: a study based on mutation screening by pyrosequencing. Melanoma Res 2006; 16: 471-8. 10.1097/01.cmr.0000232300.22032.86
- Johnson DB, Lovly CM, Flavin M, Panageas KS, Ayers GD, Zhao Z, et al. Impact of NRAS mutations for patients with advanced melanoma treated with immune therapies. Cancer Immunol Res 2015; 3: 288-95. 10.1158/2326-6066.CIR-14-0207.
- Carvajal RD, Antonescu CR, Wolchok JD, Chapman PB, Roman RA, Teitcher J, et al. KIT as a therapeutic target in metastatic melanoma. JAMA 2011; 305: 2327-34. 10.1001/jama.2011.746